Dosing

KISQALI 400 mg adjuvant dosing schedule. *⁽¹⁾

KISQALI has a once-daily dosing regimen. The recommended starting dose is 400 mg, chosen to reduce both the risk of recurrence and dose-dependent adverse reactions. ⁽¹⁾

KISQALI can be taken with or without food. Patients should be encouraged to take their dose at approximately the same time each day, preferably in the morning.

Leave no eligible patient behind. Add KISQALI up to 1 year after starting ET. ⁽²⁾

Dosing schedule for KISQALI in a 28-day cycle: KISQALI is taken daily (2 x 200 mg tablets) for 3 weeks followed by 1 week off. NSAI is taken continuously throughout the cycle, including the off week. The cycle repeats every 28 days.

* KISQALI is prescribed in combination with KISQALI in combination with an AI is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. KISQALI should not be co-administered with tamoxifen. Please refer to the respective Summary of Product Characteristics for more information on dosing. ⁽¹⁾

^† Continue KISQALI until completion of 3 years of treatment or until disease recurrence or unacceptable toxicity occurs. ⁽¹⁾

Abbreviations

AI, aromatase inhibitor; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; LHRH, luteinising hormone-releasing hormone.

References

KISQALI (ribociclib). Summary of Product Characteristics.
Slamon DJ, et al. Ther Adv Med Oncol. 2023;15:1-16.

Monitoring and dosing

Dosing

KISQALI 400 mg adjuvant dosing schedule. *(1)

KISQALI 400 mg adjuvant dosing schedule. *⁽¹⁾